Mandate

Vinge advises Industrifonden on the investment in Aprea AB

November 07, 2007

Vinge advises Industrifonden on its investment in Aprea AB, a pharmaceutical company that develops and carries out research on a new drug against cancer. Aprea will raise MSEK 50 through this share issue of which Industrifonden contributes with MSEK 25 and will thereby become a new owner in the company.

Industrifonden is represented by partner Johan Winnerblad with assistance from Johan Larsson.

Related

Vinge advises the founders of Modular Finance in connection with a transaction with Sprints

Vinge advises the founders of Modular Finance in connection with a sale of approximately 40% of the shares in the company to Sprints.
December 08, 2023

Vinge has advised Oxx in connection with the establishment of Oxx II

Oxx closes its second fund generation with USD 190 million in commitments from an international investor base, and thereby increases the fund size by 40% since its latest fund announcement.
December 07, 2023

Vinge has advised Cell Impact in connection with its rights issue

Vinge has advised Cell Impact AB (publ) in connection with a partly guaranteed rights issue which will provide Cell Impact with issue proceeds of SEK 129 million before deduction of transaction costs
December 06, 2023